Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and Challenges

J Anderson; M Lavender; E Lau; D Celermajer; N Collins; N Dwyer; J Feenstra; M Horrigan; D Keating; A Keogh; E Kotlyar; B Ng; S Proudman; P Steele; V Thakkar; R Weintraub; H Whitford; T Williams; J Wrobel; G Strange

Journal article

Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and Challenges

J Anderson, M Lavender, E Lau, D Celermajer, N Collins, N Dwyer, J Feenstra, M Horrigan, D Keating, A Keogh, E Kotlyar, B Ng, S Proudman, P Steele, V Thakkar, R Weintraub, H Whitford, T Williams, J Wrobel, G Strange

Heart Lung and Circulation | ELSEVIER SCIENCE INC | Published : 2020

DOI: 10.1016/j.hlc.2020.01.017

Abstract

Background: Combination drug therapy for pulmonary arterial hypertension (PAH) is the international standard of care for most patients, however in Australia there are barriers to drug access. This study evaluates current treatment of PAH patients in Australia and the consistency of therapy with international guidelines. Methods: Cross-sectional analysis of patients with Group 1 PAH enrolled in the Pulmonary Hypertension Society of Australia and New Zealand Registry (PHSANZ) at 31 December 2017. Drug treatment was classified as monotherapy or combination therapy and adequacy of treatment was determined by risk status assessment using the Registry to Evaluate Early and Long-Term PAH Disease Ma..

View full abstract